The Role of microRNAs and circularRNAs in diagnostic, Prognostic and therapy response as Personalized Oncology Biomarkers in prostate cancer
The Role of microRNAs and circularRNAs in diagnostic, Prognostic and therapy response as Personalized Oncology Biomarkers in prostate cancer
Alireza Akhzari,1,*
1. MSC student of Genetics, Department of Biology, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, iran
Introduction: Small noncoding RNAs known as microRNAs (miRNAs) control protein expression at the post transcriptional level as well as Circular RNAs (circRNAs) are a unique family of noncoding RNAs that could regulate multiple biological processes, which play a crucial role in carcinogenesis, progression and chemotherapy resistance of cancers. These RNAs influence a wide range of biologic processes and are often deregulated in cancer .circRNAs and microRNAs play a key roles in the development of cancer and are therefore a potential marker for diagnosis, prognosis, and therapeutic choices in prostate cancer (PCa) patients. To review the currently available data on circRNAs and microRNAs as biomarkers in PCa and as possible tools for early detection and prognosis.
Methods: Review was performed searching the PubMed and ، Science direct، Embase، Cochran و Scopus database for articles in English using the following terms: circularRNA, circRNA, microRNAs ,miRNAs ,cancer, prostate cancer, circRNA and miRNAs profiling, diagnosis, prognosis, therapy response, and predictive marker.
We summarize the existing literature concerning the profiling of circRNA and microRNAs in PCa detection, prognosis, and response to therapy
Results: The circRNAs and miRNAs are important regulators of biologic processes in PCa progression. A common expression profile characterizing each tumor subtype and stage has been identified for Pca diagnosis,prognosis and therapy response,. Large-scale studies that should provide additional important information are still missing. Further studies, based on common clinical parameters and guidelines, are necessary to validate the translational potential of circRNAs and miRNAs in PCa clinical management.
Conclusion: The literature shows that circularRNAs and miRNAs hold potential as novel biomarkers that would aid prostate cancer management, but additional studies with larger patient cohorts and common guidelines are necessary before clinical implementation.